Hudson Bay Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.73M | Sell |
304,772
-193,907
| -39% | -$1.74M | 0.01% | 498 |
|
|
2025
Q1 | $3.74M | Buy |
+498,679
| New | +$3.74M | 0.01% | 409 |
|
|
2024
Q3 | – | Sell |
-180,000
| Closed | -$1.11M | – | 659 |
|
|
2024
Q2 | $1.11M | Sell |
180,000
-120,000
| -40% | -$742K | 0.01% | 484 |
|
|
2024
Q1 | $1.52M | Buy |
300,000
+170,000
| +131% | +$864K | 0.01% | 422 |
|
|
2023
Q4 | $779K | Buy |
130,000
+65,000
| +100% | +$389K | ﹤0.01% | 462 |
|
|
2023
Q3 | $460K | Buy |
65,000
+300
| +0.5% | +$2.12K | ﹤0.01% | 519 |
|
|
2023
Q2 | $455K | Buy |
64,700
+22,200
| +52% | +$156K | ﹤0.01% | 560 |
|
|
2023
Q1 | $354K | Buy |
42,500
+17,500
| +70% | +$146K | ﹤0.01% | 590 |
|
|
2022
Q4 | $287K | Buy |
+25,000
| New | +$287K | ﹤0.01% | 692 |
|
|
2019
Q2 | – | Sell |
-140,000
| Closed | -$1.14M | – | 383 |
|
|
2019
Q1 | $1.14M | Buy |
140,000
+10,000
| +8% | +$81.4K | 0.01% | 316 |
|
|
2018
Q4 | $1.05M | Sell |
130,000
-90,000
| -41% | -$726K | 0.01% | 352 |
|
|
2018
Q3 | $1.68M | Sell |
220,000
-80,000
| -27% | -$611K | 0.02% | 305 |
|
|
2018
Q2 | $1.72M | Sell |
300,000
-260,000
| -46% | -$1.49M | 0.02% | 304 |
|
|
2018
Q1 | $2.67M | Buy |
+560,000
| New | +$2.67M | 0.06% | 215 |
|